Five Cholesterol Letters in One Day: Sweep Mechanics

who received letters on november 14 2022?

Five companies received FDA warning letters dated November 14, 2022, all in the cholesterol and cardiovascular supplement space: iwi, BergaMet North America LLC, Essential Elements, Chambers' Apothecary and Anabolic Laboratories Inc. Every letter carried the same subject line, New Drug/Misbranded — FDA's charge that a product behaves like an unapproved drug — and every one came from the agency's food and supplement division, then called CFSAN.

We found no sixth recipient dated the same day in FDA's public index.

FDA's warning-letter database lets you filter by issue date and by division, and pulling that filter for 11/14/2022 under the food program returns exactly these five — a fact we checked against the FDA warning letter database's filtered cholesterol export. A five-letter cluster on one date, in one narrow product category, from one office, isn't a coincidence of timing.

what charge did all five share?

All five shared an identical two-part charge: New Drug/Misbranded. FDA classified each product as an unapproved new drug under the Food, Drug and Cosmetic Act because it was intended to treat or prevent disease, and separately found the labeling misbranded because a layperson can't safely self-treat a disease as serious as elevated cholesterol without a prescriber's supervision. That combination means the violation exists independent of how careful the copy sounds — there's no wording fix once cholesterol is the named target.

The reason the ceiling sits this low is a decision FDA made in its own 2000 rulemaking: it treats an elevated cholesterol number as the disease itself, not as a risk factor a supplement can address the way a vitamin addresses a deficiency. FDA wrote in its 2000 rulemaking that "elevated blood pressure (hypertension) and elevated cholesterol (hypercholesterolemia) are diseases themselves, with subsequent events (heart attack, stroke) the late consequences of those diseases." The agency went on to reject the industry's preferred workaround too, ruling out "maintains healthy cholesterol" because the word "healthy" had by then come to mean HDL, the "good" cholesterol carrier, specifically — which made the phrase misleading in the opposite direction. What survives is narrower than most advertisers assume: "helps to maintain cholesterol levels that are already within the normal range" is lawful; any version of "lowers cholesterol" — hedged, qualified, or routed through an ingredient — is not.

how does a sweep get built from claim language?

A sweep gets built by running FDA's claim-language search against label copy, websites, social posts and third-party marketplace listings, then citing whichever properties use the flagged vocabulary in the same window. The agency isn't reading every supplement site cold — it's pattern-matching phrases like "reduces LDL," "lowers cholesterol" and "clinically proven" against a growing library of prior violations, then pulling the current crop of matches into one batch.

BergaMet's own product page supplied the clearest match. FDA quoted the site's claim that "BergaMet Cholesterol Command is clinically proven to improve cholesterol levels. It reduces LDL," alongside the product's own name and a money-back guarantee tied to LDL — the low-density lipoprotein carrier — improvement, three independent pieces of evidence from one page. A Walmart third-party listing describing "a bergamot supplement for high cholesterol" gave FDA a fourth data point it didn't have to write itself.

Essential Elements shows the hedge doesn't change the outcome. FDA cited the blunt "Helps Reduce LDL Levels" and the heavily softened Amazon copy claiming to help the body "potentially lowering bad cholesterol levels" as equally probative — proof that qualifying language slows nothing down once the underlying claim names the same disease.

how does this compare to the 2021 diabetes sweep?

The November 2022 cholesterol batch is the smaller of the two documented same-day sweeps in this record — five letters against the ten FDA sent on September 7, 2021 for diabetes claims, a batch we cover in full in Ten Diabetes Warning Letters in One Day. Both share the same charge family and the same office.

Line the two up and the mechanics repeat almost exactly — same claim-density trigger, same division — with the diabetes batch simply twice the size and one vertical over.

The diabetes batch is also where the hashtag evidence comes from — FDA quoted Instagram tags like #type2diabetic straight out of the Lysulin letter, alongside a testimonial reporting an HbA1c drop from 10.5% to 9.5%, a detail we unpack in Lysulin: When Hashtags Became Drug Evidence. Social copy counted as labeling in both sweeps, and neither niche got any benefit from a private account or a since-deleted post — the letters simply cite what was visible on the date FDA looked.

what does batch enforcement mean for a small operator?

It means brand size buys no protection — the trigger is vocabulary, not revenue. iwi sits in a different weight class than a bootstrapped Amazon seller, and it got the same subject line as Essential Elements on the same day, because both used the same flagged phrase family. The assumption we hear most often from smaller advertisers — that FDA is too busy to notice a small account — doesn't hold up against this record.

FDA also closed the softening loophole in that same rulemaking, writing plainly that "FDA continues to believe that 'lowers cholesterol,' however qualified, is an implied disease claim." That single line kills the entire hedge-your-way-out strategy — "may help lower," "supports lower," "clinically shown to lower" — before an advertiser even opens a draft. For a fuller picture of why raw letter counts mislead on risk, see Warning Letter Counts Are a Bad Risk Ranking.

Batch risk is claim risk, not company risk.

which claim phrases appear across multiple letters in the batch?

Four phrase families recur across the two letters we have full claim text for — BergaMet's and Essential Elements' — and they map onto the same failure modes FDA has cited going back to 2000: the direct lowering claim, the hedged version of the same claim, the guarantee tied to a lab number, and the third-party or social surface an advertiser doesn't fully control.

We could not verify the specific phrases FDA quoted from the Chambers' Apothecary and Anabolic Laboratories letters — the detailed claim record here covers only iwi, BergaMet and Essential Elements; reading those two letters directly on fda.gov would settle exactly what tripped them. The narrow language that does survive this vertical follows a different logic entirely, and it's worth checking against before you assume every cholesterol claim is off the table.

• Direct lowering claims — BergaMet's product page said "It reduces LDL," quoted straight from the site.
• Hedged versions of the same claim — Essential Elements' Amazon copy claimed to help the body "potentially lowering bad cholesterol levels," and FDA treated it as equally probative despite the softening.
• Guarantee wording tied to a lab number — BergaMet's refund offer promised money back "if they do not improve your LDL levels," which FDA read as a claim in its own right.
• Third-party marketplace listings — a Walmart page describing BergaMet as "a bergamot supplement for high cholesterol," cited even though the brand didn't write it.
• Social endorsement by reply — FDA quoted a Facebook commenter's reply that BergaMet had "liked," reading the line "it brought down all my levels out of the red and into a very healthy range" as an endorsed testimonial.

how should an offer be audited the month after a sweep lands?

Audit five surfaces the same week a sweep lands, because FDA reads them as one file: the product name, the guarantee copy, the ingredient-education tab, your own social replies, and any marketplace listing you don't directly control. BergaMet's letter shows exactly this — a compliant-sounding landing page sitting next to a Walmart listing the brand never wrote, and a Facebook reply the brand only "liked," were treated as part of the same evidentiary record. A page that reads clean in isolation can still fail once everything connected to it gets pulled together.

Pull your product name against the disease word first — "Cholesterol Command" was cited before FDA reached a single sentence of body copy — then check whether your refund guarantee references a lab value, because a guarantee tied to LDL functions as a claim on its own. If you're deciding whether to run an offer at all, validating it against live ad data first surfaces this kind of exposure before spend does.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, A Bulging-Leg Before/After Is the Disease Claim, A Heart Icon Can Be the Disease Claim by Itself, Immune Copy Breaks on Specificity, Not Intensity, Immune Claims: Brand, Retailer and Officers All Paid, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.